Stop TB Partnership, Pharmaceutical Company Announce New Initiative To Help Developing Countries Access Drug For MDR-TB

Stop TB Partnership: Stop TB Partnership’s Global Drug Facility jumpstarts access to new drugs for multidrug-resistant tuberculosis with innovative public-private partnerships
“A new initiative to enable developing countries to access delamanid — one of two new life-saving drugs approved to combat multidrug-resistant (MDR) tuberculosis (TB) — [was on Wednesday] announced by the Stop TB Partnership and Otsuka, the drug’s manufacturer. The innovative public-private partnership will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility, which already supports the USAID donation for bedaquiline — the other recently approved drug for MDR-TB, manufactured by Janssen…” (2/24).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.